Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag 2020 Revenues up 8 Percent

NEW YORK — Theradiag reported on Monday an 8 percent year-over-year increase in revenues for 2020 on strong sales of its theranostics products.

For the 12-month period ended Dec. 31, 2020, Theradiag's revenues rose to €10.4 million ($12.6 million) from €9.6 million the year before. Theranostics sales climbed almost 16 percent to €5.1 million from €4.4 million, with the company's Tracker line of therapeutic drug monitoring tests selling particularly well in the US, where the products are commercialized in collaboration with HalioDx.

In vitro diagnostics revenues, meanwhile, edged up 2 percent to €5.3 million from €5.2 million with €900,000 in sales of Theradiag's SARS-CoV-2 antigen tests and related products helping to offset the impact of nonrecurring instrumentation sales recorded in 2019.

At the end of 2020, Croissy Beaubourg, France-based Theradiag had cash totaling €3.5 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.